<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129805</url>
  </required_header>
  <id_info>
    <org_study_id>MCI9042-15</org_study_id>
    <nct_id>NCT00129805</nct_id>
  </id_info>
  <brief_title>Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)</brief_title>
  <official_title>Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-HT)
      levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic
      peripheral arterial disease.

      S-ACCESS was a randomized, double-blinded trial to compare the relative efficacy of
      sarpogrelate (100mg three times daily) and aspirin (81mg once daily) in 1510 patients with
      recent cerebral infarction. Patients were followed for 0.9 to 3.5 years. The primary endpoint
      was recurrence of cerebral infarction; relative safety was also assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence of cerebral infarction</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>intracerebral hemorrhage, subarachnoid hemorrhage, undetermined stroke, transient ischemic attack, myocardial infarction, unstable angina, or vascular death</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1510</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>MCI-9042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCI-9042</intervention_name>
    <arm_group_label>MCI-9042</arm_group_label>
    <other_name>Sarpogrelate(INN)</other_name>
    <other_name>ANPLAG(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cerebral infarction except cardiac source of embolism

          -  Onset ≧ 1 week to ≦ 6 months before randomization

          -  Neurological signs persisting ≧ 1 day from onset

          -  Computed tomography (CT) or magnetic resonance imaging (MRI) detection of responsible
             site

          -  Age ≧ 20 years

          -  Systolic pressure ≦ 180 mmHg; diastolic pressure ≦ 110 mmHg

        Exclusion Criteria:

          -  Functional outcome at randomization: Modified Rankin Scale = 4, 5

          -  Previous or planned vascular surgery for cerebral infarction

          -  History of intracranial hemorrhage

          -  History of systemic bleeding, or other history of bleeding diathesis or coagulopathy

          -  Severe complications (renal or hepatic insufficiency, heart failure, hemopathy, etc.)

          -  Pregnant or possibly pregnant women, or nursing mothers

          -  History of sarpogrelate and aspirin sensitivity

          -  Treating malignant tumor or treated within 5 years

          -  Current peptic ulceration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yukito Shinohara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K, Tohgi H, Fukuuchi Y, Uchiyama S, Yamaguchi T, Kobayashi S, Kondo K, Otomo E, Gotoh F; S-ACCESS Study Group. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke. 2008 Jun;39(6):1827-33. doi: 10.1161/STROKEAHA.107.505131. Epub 2008 Apr 3.</citation>
    <PMID>18388340</PMID>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2005</study_first_submitted>
  <study_first_submitted_qc>August 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2005</study_first_posted>
  <last_update_submitted>August 18, 2008</last_update_submitted>
  <last_update_submitted_qc>August 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>General Manager, Clinical Research Department I</name_title>
    <organization>Mitsubishi Tanabe Pharma Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Sarpogrelate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

